Cell Therapeutics (WKN: A0Q8RP ; ISIN: US1509345039) scheint in Übernahmegesprächen mit Repros Therapeutics, Inc. (WKN: 899826 ; ISIN: US98975L1089 ; NASDAQ: RPRX) zu stehen. Der Kurs beider Firmen, vor allem der von CTIC hat deutlich zugelegt:
"Recent reports suggest that not only is Big Pharma active in acquisitions, but also larger biotech firms are showing willingness to utilize their large resource pools to acquire smaller firms in a race to diversify and to build their reach. The Bedford Report examines the outlook for companies in the Biotechnology Industry and provides research reports on Cell Therapeutics, Inc. (NASDAQ: CTIC) and Repros Therapeutics, Inc. (NASDAQ: RPRX). Access to the full company reports can be found at:
Quelle: http://www.marketwire.com/press-release/...oised-to-Surge-1413080.htm |
